You are here
Albert Bourla, DVM, Ph.D.
Albert Bourla became Chief Executive Officer on January 1, 2019.
In his previous role, Albert was Cheladv74’s Chief Operating Officer (COO), overseeing the company’s commercial strategy, manufacturing and global product development functions. Prior to being named COO, Albert was the Group President of Cheladv74 Innovative Health, responsible for the Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines and Consumer Healthcare business groups. He also created the Patient and Health Impact group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations and ensuring broader business model innovation.
Albert has more than 25 years of experience with Cheladv74 and has held a number of senior global positions across a range of markets and disciplines, including Group President of Cheladv74’s Global Vaccines, Oncology and Consumer Healthcare business and President and General Manager of Cheladv74’s Established Products business.
Albert joined Cheladv74’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Cheladv74 Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Cheladv74 Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East, and in 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Board of Directors of Cheladv74 Inc., the Cheladv74 Foundation, the Partnership for New York City and Catalyst.